BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang ST, Menias CO, Lubner MG, Mellnick VM, Hara AK, Desser TS. Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. Radiographics 2017;37:1461-82. [PMID: 28753381 DOI: 10.1148/rg.2017160162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Thomas R, Sebastian B, George T, Majeed NF, Akinola T, Laferriere SL, Braschi-Amirfarzan M. A review of the imaging manifestations of immune check point inhibitor toxicities. Clin Imaging 2020;64:70-9. [PMID: 32334270 DOI: 10.1016/j.clinimag.2020.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen F, Patel NJ, Legout JD, Caserta MP. Development of complex renal cysts: A complication associated with Crizotinib therapy. Clin Imaging 2020;65:15-7. [PMID: 32353713 DOI: 10.1016/j.clinimag.2020.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 López Sala P, Alberdi Aldasoro N, Unzué García-falces G. Adverse events of targeted anticancer therapies: What radiologists need to know. Radiología (English Edition) 2020;62:229-42. [DOI: 10.1016/j.rxeng.2020.03.010] [Reference Citation Analysis]
4 Adamo DA, Sheedy SP, Menias CO, Wells ML, Fidler JL. Malabsorption Syndromes, Vasculitis, and Other Uncommon Diseases. Magn Reson Imaging Clin N Am 2020;28:55-73. [PMID: 31753237 DOI: 10.1016/j.mric.2019.09.001] [Reference Citation Analysis]
5 Tamir S, Gavrielli S, Abitbol C, Tau N, Grubstein A, Neiman V, Yosef L, Atar E, Zer A. Association between multitarget tyrosine kinase inhibitors and changes in CT appearance of submucosal fat in the gastrointestinal tract. Tumori 2021;107:432-9. [PMID: 33594961 DOI: 10.1177/0300891621995893] [Reference Citation Analysis]
6 Bustos Fiore A, Gutiérrez AB, Acosta LG, Segura Cros C, Ramos de la Rosa R. Immunotherapy in oncology: a new challenge for radiologists. Radiologia (Engl Ed) 2019;61:134-42. [PMID: 30580817 DOI: 10.1016/j.rx.2018.10.009] [Reference Citation Analysis]
7 Masui K, Hama Y, Sawada A, Akamatsu S, Sakaue J, Okabe M, Kobayashi T. A rare case of intestinal lymphangiectasia induced by pazopanib. Int Canc Conf J 2022;11:87-90. [DOI: 10.1007/s13691-021-00527-6] [Reference Citation Analysis]
8 Hosokawa T, Hara T, Arakawa Y, Oguma E, Yamada Y. Periosteal Reaction Possibly Induced by Pazopanib: A Case Report and Literature Review. J Pediatr Hematol Oncol 2020;42:e822-5. [PMID: 31567787 DOI: 10.1097/MPH.0000000000001595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Salari R, Ballard DH, Hoegger MJ, Young D, Shetty AS. Fat-only Dixon: how to use it in body MRI. Abdom Radiol (NY) 2022. [PMID: 35583822 DOI: 10.1007/s00261-022-03546-w] [Reference Citation Analysis]
10 Awiwi MO, Naik S. Tyrosine Kinase Inhibitor-related Intestinal Lymphangiectasia. Radiology 2022;:220137. [PMID: 35670716 DOI: 10.1148/radiol.220137] [Reference Citation Analysis]
11 López Sala P, Alberdi Aldasoro N, Unzué García-falces G. Efectos adversos de las terapias dirigidas contra el cáncer: lo que el radiólogo debe saber. Radiología 2020;62:229-42. [DOI: 10.1016/j.rx.2019.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]